Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.
A phase-I clinical trial of a murine monoclonal antibody that specifically suppresses growth of human gastrointestinal tumours in athymic mice was conducted in four patients, who were given 15-200 mg purified antibody. The monoclonal antibody persisted in the circulation for more than a week when more than 15 mg was given. Antibodies against mouse immunoglobulin developed in three of the four patients. In one patient who received autologous mononuclear cells that had been mixed with monoclonal antibody by way of a hepatic-artery catheter, hepatic metastases became smaller and their echogenic characteristics changed, and there was heavier monocyte infiltration in the histological appearance of a resected metastasis.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007124:Immunoenzyme Techniques; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary; D051379:Mice; D009362:Neoplasm Metastasis
D000906:Antibodies; D000911:Antibodies, Monoclonal